Laromustine

Summary

Laromustine (CHEMBL167691) is a phase-3 clinical-stage small molecule; indicated across 7 conditions including leukemia and lung neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 7 conditions
• Clinical trials: 15
• Chemistry: 307.8 Da · C6H14ClN3O5S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL167691
Name	Laromustine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	3081349
Molecular formula	C6H14ClN3O5S2
Molecular weight	307.8
InChIKey	PVCULFYROUOVGJ-UHFFFAOYSA-N

SMILES: CNC(=O)N(N(CCCl)S(=O)(=O)C)S(=O)(=O)C

IUPAC name: 1-[2-chloroethyl(methylsulfonyl)amino]-3-methyl-1-methylsulfonylurea

Also known as: 101M, Cloretazine, Laromustin, Laromustina, Laromustine, NSC-734246, Onrigin, VNP-40101M, VNP40101M, LAROMUSTINE

Patent coverage: 154 distinct patent families (370 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

7 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
leukemia	3	MONDO:0005059	EFO:0000565
lung neoplasm	2	MONDO:0021117	MONDO:0008903
myelodysplastic syndrome	1	MONDO:0018881	EFO:0000198
acute myeloid leukemia	1	MONDO:0018874	EFO:0000222
lymphoma	1	MONDO:0005062	EFO:0000574
central nervous system neoplasm	1	MONDO:0006130	EFO:1000158
neoplasm	1	MONDO:0005070	MONDO:0004992

Clinical trials

Total trials: 15.

Phase distribution

Phase	Trials
PHASE1	8
PHASE2	3
PHASE1/PHASE2	3
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00112554	PHASE3	COMPLETED	Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia
NCT00083187	PHASE2	COMPLETED	VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia
NCT00282022	PHASE2	COMPLETED	VNP40101M in Treating Patients With Relapsed or Refractory Locally Advanced or Metastatic Small Cell Lung Cancer
NCT00304005	PHASE1/PHASE2	COMPLETED	VNP40101M in Treating Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disorders
NCT00354276	PHASE2	UNKNOWN	VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia
NCT00655395	PHASE1/PHASE2	TERMINATED	Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine
NCT00840684	PHASE1/PHASE2	COMPLETED	Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia
NCT00025129	PHASE1	COMPLETED	VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas
NCT00049686	PHASE1	COMPLETED	VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome
NCT00049699	PHASE1	COMPLETED	VNP40101M in Treating Patients With Advanced or Metastatic Cancer
NCT00070538	PHASE1	COMPLETED	VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies
NCT00098436	PHASE1	COMPLETED	Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias
NCT00098761	PHASE1	COMPLETED	VNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain Tumors
NCT00516282	PHASE1	TERMINATED	VNP40101M and Temozolomide in Treating Patients With Progressive or Relapsed Malignant Glioma
NCT00521859	PHASE1	COMPLETED	Cloretazine (VNP40101M) With Hematopoietic Cell Transplantation for Hematologic Malignancies

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).